Clinical trial
Sunitinib Malate in Patients With Non-Clear Cell Renal Cell Cancer
NCT00465179 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00465179 |
|---|---|
| Title | Sunitinib Malate in Patients With Non-Clear Cell Renal Cell Cancer |
| Official title | Phase II Trial of Sunitinib Malate (Sutent) Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Pfizer Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Renal Cell Cancer, Kidney Cancer |
| Intervention type | Drug |
| Interventions | Sunitinib Malate |
| Enrollment | 61 |
| Start date | Mar 1, 2007 |
| Primary completion | Mar 1, 2015 |
| Completion | Mar 1, 2015 |
| First posted | Apr 24, 2007 |
| Last update posted | Jun 7, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: